Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

被引：54

作者：

Cho, B-S ^{[1
]}

Min, C-K ^{[1
]}

Eom, K-S ^{[1
]}

Kim, Y-J ^{[1
]}

Kim, H-J ^{[1
]}

Lee, S. ^{[1
]}

Cho, S-G ^{[1
]}

Kim, Y. ^{[2
]}

Kim, D-W ^{[1
]}

Lee, J-W ^{[1
]}

Min, W-S ^{[1
]}

Kim, C-C ^{[1
]}

机构：

[1] Catholic Univ, Catholic Hematopoiet Stem Cell Transplantat Ctr, Dept Hematol, Seoul, South Korea

[2] Catholic Univ, Dept Clin Pathol, Seoul, South Korea

来源：

BONE MARROW TRANSPLANTATION | 2008年 / 41卷 / 09期

关键词：

acute graft-versus-host disease; thrombotic microangiopathy; allogeneic hematopoietic stem cell transplantation; survival; prognostic factors;

D O I：

10.1038/sj.bmt.1705976

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The impact of thrombotic microangiopathy (TMA) on outcome was studied in 148 patients with acute graft-versus-host disease (GVHD) (>= grade II). The Blood and Marrow Transplant Clinical Trials Network's definition for TMA was used to diagnose definite TMA. Probable TMA was diagnosed when none of the features of nephropathy and neurologic abnormalities associated with definite TMA were present. Overall, TMA developed in 43 (29%) patients; 16 definite and 27 probable. The occurrence of TMA, the maximum grade of acute GVHD and initial treatment failure were associated with shorter overall and GVHD-specific survival. The development of probable as well as definite TMA affected the survival of patients with acute GVHD adversely. These results show the clinical impact of TMA on patients with acute GVHD, and suggest that the proposed definitions and grading of TMA may need to be modified.

引用

页码：813 / 820

页数：8

共 37 条

[1] Long-term outcome after bone marrow transplantation for severe aplastic anemia [J].

Ades, L ;

Mary, JY ;

Robin, M ;

Ferry, C ;

Porcher, R ;

Esperou, H ;

Ribaud, P ;

Devergie, A ;

Traineau, R ;

Gluckman, E ;

Socié, G .

BLOOD, 2004, 103 (07) :2490-2497

[2] Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease [J].

Biedermann, BC ;

Sahner, S ;

Gregor, M ;

Tsakiris, DA ;

Jeanneret, C ;

Pober, JS ;

Gratwohl, A .

LANCET, 2002, 359 (9323) :2078-2083

[3] Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: A single-center experience in Korea [J].

Choi, SM ;

Lee, DG ;

Choi, JH ;

Yoo, JH ;

Kim, YJ ;

Park, SH ;

Park, SN ;

Min, CK ;

Lee, S ;

Kim, HJ ;

Kim, DW ;

Lee, JW ;

Min, WS ;

Shin, WS ;

Kim, CC .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 81 (01) :69-74

[4] A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease [J].

Cragg, L ;

Blazar, BR ;

Defor, T ;

Kolatker, N ;

Miller, W ;

Kersey, J ;

Ramsay, N ;

McGlave, P ;

Filipovich, A ;

Weisdorf, D .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (4A) :441-447

[5] Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation [J].

Cutler, C ;

Henry, NL ;

Magee, C ;

Li, SL ;

Kim, HT ;

Alyea, E ;

Ho, V ;

Lee, SJ ;

Soiffer, R ;

Antin, YH .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (07) :551-557

[6] The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation [J].

Fuge, R ;

Bird, J M ;

Fraser, A ;

Hart, D ;

Hunt, L ;

Cornish, JM ;

Goulden, N ;

Oakhill, A ;

Pamphilon, DH ;

Steward, CG ;

Marks, DI .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (01) :58-64

[7] Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma [J].

George, JN ;

Li, XN ;

McMinn, JR ;

Terrell, DR ;

Vesely, SK ;

Selby, GB .

TRANSFUSION, 2004, 44 (02) :294-304

[8] Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion [J].

Hahn, T ;

Alam, AR ;

Lawrence, D ;

Ford, L ;

Baer, MR ;

Bambach, B ;

Bernstein, ZP ;

Czuczman, MS ;

Silva, J ;

Slack, JL ;

Wetzler, M ;

Becker, J ;

McCarthy, PL .

TRANSPLANTATION, 2004, 78 (10) :1515-1522

[9] Hemolytic uremic syndrome after bone marrow transplantation: Clinical characteristics and outcome in children [J].

Hale, GA ;

Bowman, LC ;

Rochester, RJ ;

Benaim, E ;

Heslop, HE ;

Krance, RA ;

Horwitz, EM ;

Cunningham, JM ;

Tong, X ;

Srivastava, DK ;

Handgretinger, R ;

Jones, DP .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (11) :912-920

[10] Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation [J].

Ho, VT ;

Cutler, C ;

Carter, S ;

Martin, P ;

Adams, R ;

Horowitz, M ;

Ferrara, J ;

Soiffer, R ;

Giralt, S .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (08) :571-575

← 1 2 3 4 →